{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:40:16Z","timestamp":1792176016177,"version":"4.4.0"},"reference-count":13,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Case Reports"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Patients undergoing chemotherapy are prone to developing hyponatremia due to insufficient oral intake because of nausea and vomiting, administration of large volumes of intravenous fluids, syndrome of inappropriate antidiuretic hormone secretion induced by chemotherapeutic agents, adrenal insufficiency, and drug interactions. Severe hyponatremia during chemotherapy interferes with continuation of cancer treatment. In addition, it may be difficult to distinguish hyponatremia from chemotherapy\u2010related adverse effects because of symptom similarity. This report presented a case of desmopressin\u2010induced severe hyponatremia during chemotherapy and discussed the appropriateness of discontinuing desmopressin administration. A 70\u2010year\u2010old male was hospitalized for postoperative adjuvant chemotherapy with cisplatin and vinorelbine for a pathological stage IIB adenocarcinoma of the right lower lung lobes. The patient had been taking oral desmopressin (25\u2009\u03bcg daily) for 4\u2009years to treat nocturnal polyuria. Desmopressin was discontinued on day 1 of chemotherapy because of a contraindicated combination with dexamethasone, which was administered as an antiemetic. Desmopressin was resumed on day 6, but was followed by Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 nausea, anorexia, and CTCAE Grade 4 hyponatremia (serum sodium concentration of 119\u2009mEq\/L) on day 7. Severe hyponatremia progressed following the resumption of desmopressin treatment. Desmopressin was not reintroduced thereafter, and subsequent chemotherapy cycles were continued without recurrence of hyponatremia. The patient completed all four planned adjuvant chemotherapy cycles. This case study highlighted the importance of carefully evaluating the necessity of continuing desmopressin administration and considering its discontinuation during chemotherapy to prevent the onset of hyponatremia.<\/jats:p>","DOI":"10.1002\/ccr3.72192","type":"journal-article","created":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T16:45:28Z","timestamp":1772988328000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Case Report of Acute Severe Hyponatremia Induced by Desmopressin Administration During Chemotherapy"],"prefix":"10.1002","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3745-9996","authenticated-orcid":false,"given":"Koutaro","family":"Ono","sequence":"first","affiliation":[{"name":"Department of Hospital Pharmaceutics Showa Medical University School of Pharmacy  Tokyo Japan"},{"name":"Department of Pharmacy Showa Medical University Northern Yokohama Hospital  Kanagawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shugo","family":"Uematsu","sequence":"additional","affiliation":[{"name":"Respiratory Disease Center Showa Medical University Northern Yokohama Hospital  Yokohama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Yoshihara","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Showa Medical University Northern Yokohama Hospital  Yokohama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Tsuboya","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmaceutics Showa Medical University School of Pharmacy  Tokyo Japan"},{"name":"Department of Pharmacy Showa Medical University Northern Yokohama Hospital  Kanagawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichi","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmaceutics Showa Medical University School of Pharmacy  Tokyo Japan"},{"name":"Department of Pharmacy Showa Medical University Northern Yokohama Hospital  Kanagawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Yoshioka","sequence":"additional","affiliation":[{"name":"Institute of Clinical Epidemiology Showa Medical University  Tokyo Japan"},{"name":"Health Technology Assessment Unit, Department of Preventive Medicine and Public Health Keio University School of Medicine  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Nawata","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmaceutics Showa Medical University School of Pharmacy  Tokyo Japan"},{"name":"Department of Pharmacy Showa Medical University Northern Yokohama Hospital  Kanagawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,3,5]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2011\u20100400"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.4103\/2230\u20108210.93734"},{"key":"e_1_2_14_4_1","unstructured":"US FDA \u201cDesmopressin Acetate (NDA 018938) Approval History\/Drug Application Overview. U.S. FDA. NDA 018938 Approval Actions and Application Overview \u201d(2026) https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=018938."},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197511062931905"},{"key":"#cr-split#-e_1_2_14_6_1.1","unstructured":"International Council for Harmonisation (ICH) M12 Drug Interaction Studies: Guidance for Industry. Final Guidance Adopted by FDA(2024) https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/m12\u2010drug\u2010interaction\u2010studiesPharmaceuticals Safety and Environmental Health Bureau Japan. Guideline on Drug Interaction for Drug Development and Appropriate Provision of Information. PSEHB Notification No. 0723-4 July 23 2018. Tokyo: Ministry of Health Labour and Welfare"},{"key":"#cr-split#-e_1_2_14_6_1.2","unstructured":"2018 accessed March 13 2021 https:\/\/www.pmda.go.jp\/files\/000228122.pdf."},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/luts.12513"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.7150\/jca.2.62"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2011.08.029"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.8.1191"},{"issue":"6","key":"e_1_2_14_11_1","first-page":"48","article-title":"Cisplatin\u2010Induced Acute Hyponatremia Leading to a Seizure and Coma: A Case Report","volume":"34","author":"Cheng C. Y.","year":"2011","journal-title":"Chang Gung Medical Journal"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.40.1020"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/SMJ.0b013e3181e63682"}],"container-title":["Clinical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ccr3.72192","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ccr3.72192","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ccr3.72192","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T06:07:17Z","timestamp":1774505237000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ccr3.72192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1002\/ccr3.72192"],"URL":"https:\/\/doi.org\/10.1002\/ccr3.72192","archive":["Portico"],"relation":{},"ISSN":["2050-0904","2050-0904"],"issn-type":[{"value":"2050-0904","type":"print"},{"value":"2050-0904","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"2025-11-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e72192"}}